Rein Therapeutics (RNTX)
NASDAQ:RNTX
Want to see RNTX full AI Analyst Report?
RNTX Stock Chart & Stats
$1.26
--
Market closed
$1.26
--
Day’s Range― - ―
52-Week Range$1.02 - $2.40
Previous CloseN/A
VolumeN/A
Average Volume (3M)228.95K
Market Cap
$46.54M
Enterprise Value$43.33M
Total Cash (Recent Filing)$3.21M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.24
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.09
Shares Outstanding28,039,032
10 Day Avg. Volume262,542
30 Day Avg. Volume228,948
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market Cap0.93
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-1.98
Forecast
1Y Price Target
$10.00Price Target Upside693.65% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-1.63
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageVery low debt materially reduces financial risk and interest burden for a clinical-stage biotech. This structural cushion gives management flexibility to prioritize R&D and clinical programs over near-term cash interest obligations, improving survival odds during multi‑quarter trials.
Improving Cash BurnA year-over-year improvement in cash burn indicates better operational control or more efficient R&D spending. If sustained, this trend extends runway and reduces near-term financing needs, enhancing the company's ability to reach clinical milestones without constant emergency financings.
Completed Private PlacementSecuring private capital via a Rule 506/Section 4(a)(2) placement is a durable structural event that extends runway and brings sophisticated investors. It provides regulatory flexibility and time to progress clinical programs, reducing immediate liquidity pressure while broadening financing options.
Bears Say
Pre‑revenue With Persistent LossesNo product revenue and sustained large net losses mean the company cannot self-fund operations. Over multiple quarters this forces reliance on external capital, creates execution risk if financings stall, and removes the stabilizing effect of operating cash generation.
Sharply Declining Equity BaseA large drop in shareholders' equity weakens the balance-sheet cushion against further losses and adverse trial outcomes. Reduced equity limits flexibility for non-dilutive funding, raises creditor and partner concerns, and amplifies the consequences of any future adverse events.
Reliance On External FundingThe company's ongoing negative free cash flow and use of exempt private placements show structural dependence on external capital. This creates persistent dilution risk, financing contingency for programs, and execution uncertainty if capital markets tighten or investor appetite wanes.
Rein Therapeutics News
RNTX FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was $1.02 and its highest was $2.40 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is $46.54M.
When is Rein Therapeutics’s upcoming earnings report date?
Rein Therapeutics’s upcoming earnings report date is May 20, 2026 which is in 24 days.
How were Rein Therapeutics’s earnings last quarter?
Rein Therapeutics released its earnings results on Apr 06, 2026. The company reported -$1.09 earnings per share for the quarter, missing the consensus estimate of -$0.49 by -$0.6.
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 28,039,032 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Rein Therapeutics reported an EPS of -$1.09 in its last earnings report, missing expectations of -$0.49. Following the earnings report the stock price went up 14.876%.
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in RNTX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$10.00 (693.65% Upside)
$10.00 (693.65% Upside)
Insider Transactions
Bought Shares
Worth $550.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.1%
Last 30 Days ▲ 22.3%
Last 30 Days ▲ 22.3%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-27.80%
12-Months-Change
Fundamentals
Return on Equity
-281.00%
Trailing 12-Months
Asset Growth
-61.89%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of a novel class of therapeutics for the treatment of cancer and other diseases. It focuses on its lead product candidate, ALRN-6924, which is a cell-permeating peptide that disrupts the interaction of p53 suppressors MDM2 and MDMX with tumor suppressor p53 to reactivate tumor suppression in non-mutant, or wild-type, p53 cancers. The company was founded by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky on August 6, 2001 and is headquartered in Austin, TX.
RNTX Stock 12 Month Forecast
Average Price Target
$10.00
▲(693.65% Upside)
Technical Analysis
―
Kezar Life Sciences
―
Vivos Therapeutics
―
OnKure Therapeutics
―
Rani Therapeutics Holdings
―
Ownership Overview
7.15% Insiders
4.47% Mutual Funds
31.09% Other Institutional Investors
52.99% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---